Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (361-370 of 1,112) with videos related to

Pageof 112
Sort By:
Archives of Internal Medicine|November 25, 2010
Metformin use and mortality among patients with diabetes and atherothrombosisRonan Roussel, Florence Travert, Blandine Pasquet, et al.
American Heart Journal|December 17, 2016
Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudyFranck Boccara, Joe Miantezila Basilua, Murielle Mary-Krause, et al.
The American Journal of Medicine|January 23, 2017
Hemoglobin and Change in Hemoglobin Status Predict Mortality, Cardiovascular Events, and Bleeding in Stable Coronary Artery DiseasePaul R Kalra, Nicola Greenlaw, Roberto Ferrari, et al.
JAMA Cardiology|November 15, 2018
Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker StudyDaniel Lindholm, Stefan K James, Katja Gabrysch, et al.
Archives of Internal Medicine|January 11, 2007
External validity of clinical trials in acute myocardial infarctionPhilippe Gabriel Steg, José López-Sendón, Esteban Lopez de Sa, et al.
Archives of Internal Medicine|September 12, 2007
Increasing use of single and combination medical therapy in patients hospitalized for acute myocardial infarction in the 21st century: a multinational perspectiveRobert J Goldberg, Frederick A Spencer, Philippe Gabriel Steg, et al.
American Heart Journal|April 1, 2009
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trialStefan James, Axel Akerblom, Christopher P Cannon, et al.
European Heart Journal|August 21, 2018
Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registryEmmanuelle Vidal-Petiot, Emmanuel Sorbets, Deepak L Bhatt, et al.
International Journal of Cardiology|March 21, 2016
Frequency and prognostic significance of access site and non-access site bleeding and impact of choice of antithrombin therapy in patients undergoing primary percutaneous coronary intervention. The EUROMAX trialSinem Kilic, Arnoud W J Van't Hof, Jurrien Ten Berg, et al.
Clinical Pharmacokinetics|January 21, 2022
Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin FormulationDominick J Angiolillo, Jayne Prats, Efthymios N Deliargyris, et al.
Pageof 112

Showing results (361-370 of 1,112) with videos related to

Sort By:
Pageof 112
Archives of Internal Medicine|November 25, 2010
Metformin use and mortality among patients with diabetes and atherothrombosisRonan Roussel, Florence Travert, Blandine Pasquet, et al.
American Heart Journal|December 17, 2016
Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudyFranck Boccara, Joe Miantezila Basilua, Murielle Mary-Krause, et al.
The American Journal of Medicine|January 23, 2017
Hemoglobin and Change in Hemoglobin Status Predict Mortality, Cardiovascular Events, and Bleeding in Stable Coronary Artery DiseasePaul R Kalra, Nicola Greenlaw, Roberto Ferrari, et al.
JAMA Cardiology|November 15, 2018
Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker StudyDaniel Lindholm, Stefan K James, Katja Gabrysch, et al.
Archives of Internal Medicine|January 11, 2007
External validity of clinical trials in acute myocardial infarctionPhilippe Gabriel Steg, José López-Sendón, Esteban Lopez de Sa, et al.
Archives of Internal Medicine|September 12, 2007
Increasing use of single and combination medical therapy in patients hospitalized for acute myocardial infarction in the 21st century: a multinational perspectiveRobert J Goldberg, Frederick A Spencer, Philippe Gabriel Steg, et al.
American Heart Journal|April 1, 2009
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trialStefan James, Axel Akerblom, Christopher P Cannon, et al.
European Heart Journal|August 21, 2018
Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registryEmmanuelle Vidal-Petiot, Emmanuel Sorbets, Deepak L Bhatt, et al.
International Journal of Cardiology|March 21, 2016
Frequency and prognostic significance of access site and non-access site bleeding and impact of choice of antithrombin therapy in patients undergoing primary percutaneous coronary intervention. The EUROMAX trialSinem Kilic, Arnoud W J Van't Hof, Jurrien Ten Berg, et al.
Clinical Pharmacokinetics|January 21, 2022
Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin FormulationDominick J Angiolillo, Jayne Prats, Efthymios N Deliargyris, et al.
Pageof 112